KOE · 468530.KQ
Proteina Co., Ltd.
₩54,300+₩400 (+0.74%)
Proteina Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.79% below the high.
Loading market information…
KOE · 215600.KQ · KRW
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
SillaJen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.59% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow SillaJen, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SillaJen, Inc. is dedicated to the advancement and commercialization of oncolytic immunotherapy products. Its primary therapeutic candidate, Pexa-Vec, is currently undergoing Phase II clinical evaluation as a potential treatment for late-stage liver cancer. The firm also has JX-970 in development, aimed at targeting tumor tissues, and the JX-900 series, which consists of modified vaccinia vaccines. Established in 2006, SillaJen is headquartered in Seoul, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:38 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩54,300+₩400 (+0.74%)
Proteina Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.79% below the high.
₩8,090-₩260 (-3.11%)
MEDIPOST Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 72.2% below the high.
₩9,970+₩70 (+0.71%)
Genomictree Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.06% below the high.
₩2,495-₩65 (-2.54%)
HLB Therapeutics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.02% below the high.
₩6,030-₩50 (-0.82%)
BINEX Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 64.11% below the high.
₩6,810-₩170 (-2.44%)
Bioneer Corporation’s quoted price sits in the lower half of its reported 52-week range, 62.06% below the high.
₩3,700+₩80 (+2.21%)
Helixmith Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 62.85% below the high.
₩13,360-₩720 (-5.11%)
Anterogen.Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 78.38% below the high.
